Cargando…

Eptinezumab for migraine prevention in patients 50 years or older

OBJECTIVE: To evaluate the efficacy and safety of eptinezumab versus placebo in patients ≥50 years old with episodic (EM) or chronic migraine (CM). MATERIALS AND METHODS: This post hoc analysis included data from two phase 3, parallel‐group, randomized, double‐blind, placebo‐controlled studies in ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Vincent, Tassorelli, Cristina, Ettrup, Anders, Hirman, Joe, Cady, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305510/ https://www.ncbi.nlm.nih.gov/pubmed/35218203 http://dx.doi.org/10.1111/ane.13603

Ejemplares similares

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
por: Blumenfeld, Andrew, et al.
Publicado: (2022)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
por: Smith, Timothy R., et al.
Publicado: (2021)

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
por: Lipton, Richard B., et al.
Publicado: (2020)

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
por: Lipton, Richard B., et al.
Publicado: (2022)

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
por: Ashina, Messoud, et al.
Publicado: (2020)

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
por: Kudrow, David, et al.
Publicado: (2021)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2022)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
por: Cady, Roger, et al.
Publicado: (2022)

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
por: Cowan, Robert P., et al.
Publicado: (2022)

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
por: Silberstein, Stephen, et al.
Publicado: (2020)

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
por: Apelian, Rami, et al.
Publicado: (2022)

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials
por: Schim, Jack D., et al.
Publicado: (2022)

Eptinezumab for migraine
Publicado: (2022)

Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
por: Baker, Brian, et al.
Publicado: (2021)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
por: McAllister, Peter, et al.
Publicado: (2022)

A Review of Eptinezumab Use in Migraine
por: Datta, Abhigyan, et al.
Publicado: (2021)

Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
por: Barbanti, Piero, et al.
Publicado: (2022)

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
por: Pederson, Susan, et al.
Publicado: (2021)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine
por: Kaniecki, Robert G., et al.
Publicado: (2023)

Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial
por: Li, Xue-Ning, et al.
Publicado: (2023)

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
por: Baker, Brian, et al.
Publicado: (2020)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
por: Bader, Yazan, et al.
Publicado: (2023)

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study
por: Jensen, Rigmor H., et al.
Publicado: (2023)

Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials
por: Yan, Zeya, et al.
Publicado: (2021)

Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention
por: Lipton, Richard B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q6llk8ucilomkbtc00e3krldot